Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Status:
RECRUITING
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3K:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.